Abstract: A catalyst includes a cyclic imide compound having an N-substituted cyclic imide skeleton represented by following Formula (I): wherein X is an oxygen atom or a hydroxyl group, and having a solubility parameter of less than or equal to 26 [(MPa)1/2] as determined by Fedors method. The catalyst may further comprise a metallic compound. By allowing (A) a compound capable of forming a radical to react with (B) a radical scavenging compound in the presence of the catalyst, an addition or substitution reaction product between the compound (A) and the compound (B) or a derivative thereof can be obtained.

Abstract: Disclosed are dirhodium catalyst compositions. One such dirhodium catalyst composition includes a dirhodium catalyst and a solid support. The dirhodium catalyst includes a Rh—Rh moiety and four bridging ligand moieties. The dirhodium catalyst and the solid support are bound together, but they are not covalently bound together via one or more of the bridging ligand moieties. Another such dirhodium catalyst composition includes a dirhodium tetracarboxylate catalyst and a solid support, and the dirhodium tetracarboxylate catalyst and the solid support are bound together. Yet another such dirhodium catalyst composition includes a dirhodium catalyst and a solid support, where the dirhodium catalyst includes a Rh—Rh moiety and where the dirhodium catalyst and the solid support are bound together via at least one of the rhodiums' axial positions. The compositions can be used in a number of reactions, including insertion reactions (e.g.

Abstract: A white or whitish luminescent material for phosphorescence is provided by synthesizing an organometallic complex that is able to convert a triplet excited state into light emission. In particular, a white electroluminescent device that has a high luminous efficiency and can be manufactured easily is provided by using the organometallic complex to manufacture a white or whitish electroluminescent device. The electroluminescent device is used to provide a light-emitting device with low power consumption. A fluorescent and phosphorescent material represented by a general formula (2) is synthesized. Since this material can emit both components of fluorescence and phosphorescence in the region of visible light, white or whitish luminescence can be achieved, which is applied to an electroluminescent device or a light-emitting device.

Abstract: Compounds having the formula: are disclosed. M1 and M2 are the same or different and are transition metal atoms or ions; Z2 and Z3, independently, are the atoms necessary to complete a 3-12 membered heterocyclic ring; Z1 is an alkylene or arylene group; Q1 and Q2 are the same or different and are electron withdrawing groups; L1 and L3, taken together, represent —O—CR13—O—; L2 and L4, taken together, represent —O—CR14—O—; and R13 and R14 are the same or different and are selected from the group consisting of alkyl groups and aryl groups or R13 and R14 represent alkylene or arylene groups that are directly or indirectly bonded to one another. Methods for making such compounds are also disclosed, as are intermediates which can be used in their preparation. Also disclosed are methods for carrying out C—H insertion reactions using bis-transition metal catalysts, such as the above compounds.

Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.

Abstract: Disclosed are dirhodium catalyst compositions. One such dirhodium catalyst composition includes a dirhodium catalyst and a solid support. The dirhodium catalyst includes a Rh—Rh moiety and four bridging ligand moieties. The dirhodium catalyst and the solid support are bound together, but they are not covalently bound together via one or more of the bridging ligand moieties. Another such dirhodium catalyst composition includes a dirhodium tetracarboxylate catalyst and a solid support, and the dirhodium tetracarboxylate catalyst and the solid support are bound together. Yet another such dirhodium catalyst composition includes a dirhodium catalyst and a solid support, where the dirhodium catalyst includes a Rh—Rh moiety and where the dirhodium catalyst and the solid support are bound together via at least one of the rhodiums' axial positions. The compositions can be used in a number of reactions, including insertion reactions (e.g.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X, T, Q, Z, U, Y, Ar, p and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: Compounds having the formula: are disclosed. M1 and M2 are the same or different and are transition metal atoms or ions; Z2 and Z3, independently, are the atoms necessary to complete a 3-12 membered heterocyclic ring; Z1 is an alkylene or arylene group; Q1 and Q2 are the same or different and are electron withdrawing groups; L1 and L3, taken together, represent —O—CR13—O—; L2 and L4, taken together, represent —O—CR14—O—; and R13 and R14 are the same or different and are selected from the group consisting of alkyl groups and aryl groups or R13 and R14 represent alkylene or arylene groups that are directly or indirectly bonded to one another. Methods for making such compounds are also disclosed, as are intermediates which can be used in their preparation. Also disclosed are methods for carrying out C—H insertion reactions using bis-transition metal catalysts, such as the above compounds.

Abstract: A compound of the formula

Abstract: Compounds of formula (I) both in the racemic and optically active forms, are used in MRI diagnostic imaging.

Abstract: A metallocene compound is provided wherein to a transition metal compound is bonded a multidentate compound wherein a substituted cycloalkadienyl ring CA1 having therein a heteroaromatic group Ra containing an oxygen, sulfur or nitrogen atom on a cycloalkadienyl ring, preferably the five-membered ring thereof, and an unsubstituted or substituted cycloalkadienyl group CA2 or —(R1)N—, —O—, —S— or —(R1)P—, preferably CA2, more preferably a substituted cycloalkadienyl group identical with CA1 are bonded through a divalent linking group. The metallocene compound is suitable as a principal ingredient of a catalyst for the polymerization of olefins, particularly achieving a very high effect in making the molecular weight of a polypropylene higher.

Abstract: A metallocene compound is provided wherein to a transition metal compound is bonded a multidentate compound wherein a substituted cycloalkadienyl ring CA1 having therein a heteroaromatic group Ra containing an oxygen, sulfur or nitrogen atom on a cycloalkadienyl ring, preferably the five-membered ring thereof, and an unsubstituted or substituted cycloalkadienyl group CA2 or —(R1)N—, —O—, —S— or —(R1)P—, preferably CA2, more preferably a substituted cycloalkadienyl group identical with CA1 are bonded through a divalent linking group. The metallocene compound is suitable as a principal ingredient of a catalyst for the polymerization of olefins, particularly achieving a very high effect in making the molecular weight of a polypropylene higher.

Abstract: The present invention is directed to a method of determining the ratio of the concentration or amounts of two or more chemical compounds and/or biopolymers, or of the relative amounts of sub-populations of closely structurally related compounds, in a multi-component mixture, extract, system, and the like using an analytical physicochemical process. The method is based on distribution of the components of the mixture (system, extract, etc.) between two or more immiscible phases and the subsequent determination of the total amounts (concentrations) of biopolymers (chemical compounds) or of the amounts (concentrations) of one or more component(s) or sub-populations of the system in the phases. The ratio between these concentrations is defined therein as the partition coefficient. The partition coefficient is used as a measure of the ratio of the amounts of two or more biopolymers (chemical compounds) or their sub-populations in a multi-component mixture (extract, system, etc.

Abstract: Novel chiral boron and aluminum hydride complexes, compositions comprising the chiral hydride complexes, and methods for their synthesis and use are described. The novel chiral hydride complexes are of the formulas:MBH.sub.4-n-a (R*).sub.n (R').sub.a ;MBH.sub.2-b (R**) (R').sub.b ;MBH(R***);MBH(R*) (R");MAlH.sub.4-n-a (R*).sub.n (R').sub.a ;MAlH.sub.2-b (R**)(R').sub.b ;MAlH(R***); andMAlH(R*) (R"),whereinM is Na.sup.+, Li.sup.+ or K.sup.+ ;each R* is independently a monodentate chiral ligand;R** is a bidentate chiral ligand;R*** is a tridentate chiral ligand;R' is a monodentate achiral ligand;R" is a bidentate achiral ligand;n is 1-3;a is 0-2; andb is 0-1,with the proviso that n+a.ltoreq.3, and with the further proviso that when R** is S-BINOL, M is not Li.sup.+.

Abstract: The present invention relates to the treatment of tumors with a novel water soluble trans-platinum coordination compound having the general structural formula [PtBX.sub.m (NR*.sub.3)] where B is a planar, heterocyclic ring containing at least one nitrogen atom, and a pendant chelating group; and X is an anionic ligand; and R* is hydrogen or a lower alkyl.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgical blood loss, acute nonvolemic hemodilutions, wounds, diabetic ulcers, chronic leg ulcers, pressure sores, tissue transplants, and sepsis. The compounds are capable of acting on hemoglobin in whole blood.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in radiation oncology applications. The compounds are capable of acting on hemoglobin in whole blood.

Abstract: A flame retardant organic silicon and phosphorus containing compound is produced by reacting a silicon halides compound with an organic phosphorus compound to produce an organic silicon and phosphorus halides compound which is then reacted with an organic compound to produce an organic silicon and phosphorus containing compound. This organic silicon and phosphorus containing compound is incorporated in an otherwise more flammable organic material under reaction conditions and in an amount sufficient to reduce the combustibility of the otherwise more flammable organic material. The organic silicon and phosphorus containing compound may also be utilized as coating agents, adhesives, surfactants, insecticides, hydraulic fluid and other uses.

Abstract: Compounds of general Formula I ##STR1## wherein R.sup.3 is a saturated, unsaturated, straight- or branched-chain or cyclic aliphatic hydrocarbon residue of up to 16 carbon atoms or, if R.sup.4 is a hydrogen atom, a cycloalkyl group or an aryl or aralkyl group optionally substituted by one or several C.sub.1 -C.sub.6 -dialkylamino groups or by one or several C.sub.1 -C.sub.6 -alkoxy groups,R.sup.4 is a hydrogen atom, a saturated, unsaturated, straight- or branched-chain or cyclic hydrocarbon residue of up to 16 carbon atoms, orR.sup.3 and R.sup.4 jointly mean a saturated or unsaturated 5- or 6-membered ring optionally substituted or containing an O, S, N atom or oxo substituent, and Y is COOX or CONR.sub.3 R.sub.4,are valuable complexing agents, complexes or complex salts, e.g., for use as NMR or X-ray diagnostic image-enhancement agents or radioactive diagnostic agents.

Abstract: A mixture of silicon and phosphorus are heated and reacted with halide to produce silicon tetrahalides, silicon-phosphorus halide and phosphorus trihalides compositions. These compositions are reacted with any suitable organic, inorganic-organic and/or inorganic compound to produce novel organic silicon-phosphorus containing compositions. These compositions may be utilized as flame retardants, coating agents, adhesives and many other uses.

Abstract: The present invention relates to a single source metalloorganic precursor compound of the formula:(2-NR-Q-).sub.l M-A.sub.m (I=0-4, m=0-4, l+m=2 or 4)wherein M is selected form the Group 14 elements of Germanium, Tin or Lead;A and R are independently selected from: amide, alkyl having from 1 to 20 carbon atoms, aryl, substituted aryl, or -Q'-2-NR'L.sub.n (n=1-4) wherein L is selected from nothing or a Lewis base ligand;Q and Q' are each independently selected from Group VIa elements of sulfur, selenium, or tellurium; and2-NR and 2-NR' are each independently selected from N-heterocyclic aryl or its derivatives.Methods of producing these compounds are also disclosed. These precursor materials provide in a single compound the binary, tertiary, or quaternary metals in a ratio to each other that is controllable by a judicious choice of metal atoms and organic substituents. The metal alloys are useful in a variety for electronic applications, particularly in semiconductors and solar energy.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgical blood loss, acute nonvolemic hemodilutions, wounds, diabetic ulcers, chronic leg ulcers, pressure sores, tissue transplants, and sepsis. The compounds are capable of acting on hemoglobin in whole blood.

Abstract: Allosteric hemoglobin modifier compound activity on p50 is potentiated by using the compound in combination with a hydrophobic compound such as an anesthetic.

Abstract: A process of enantioselective synthesis of seven-membered carbocycles in the presence of di-rhodium(II) tetracarboxylate catalysts.

Abstract: Compounds of formula (I): ##STR1## in which: A and B are separately monoamines or together diamines; and Z is a group of formula (II) or (III): ##STR2## (in which R.sup.1, R.sup.2 and R.sup.7 are various organic groups, n is 0, 1 or 2 and X is a direct carbon-carbon bond or lower alkylene) show valuable anti-tumor activity and may be prepared by reacting an amine-platinum complex with a compound providing the group represented by Z.

Abstract: The present invention relates a precursor metal organic compound of the formula:2-NR-Q-M-Awherein M is selected from the Group IIb elements of Zinc, Cadmium, of Mercury;A is selected from R: Amide, alkyl having from 1 to 20 carbon atoms, aryl, substituted aryl, or -Q'-2-NR'L2 wherein L is selected from nothing or a Lewis base ligand,Q and Q' are each independently selected from Group VIa elements of sulfur, selenium, or tellurium; and2-NR and 2-NR" are each independently selected from N-heterocyclic aryl or its derivatives.In a preferred embodiment, A is -Q'-2-NR' and L is nothing, especially wherein 2-NR=2-NR', Q=Q'. Methods of producing these compounds are also disclosed. These precursor materials provide in a single compound the binary, tertiary, or quaternary metals in a ratio to each other that is controllable by a discerning choice of metal atoms and organic constituents. The metal alloys are useful in a variety of electronic applications, particularly in semiconductors.

Abstract: A compound of the general formula ##STR1## or a salt or complex thereof, in which X, Y and Z are all optionally substituted carbon atoms and R is hydrogen, optionally substituted hydrocarbyl or acyl or --COOR.sup.7 and R.sup.7 is hydrocarbyl has anti-microbial properties. Particular examples are compounds in which X is --CH.sub.2 -- or --C(CH.sub.3).sub.2 -- and Y and Z are both --CH.sub.2 -- or X is is --CH.sub.2 -- and Y and Z are carbon atoms of a benzene ring. The zinc complexes have useful properties.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: A compound of the general formula ##STR1## or a salt or complex thereof, in which X, Y and Z are all optionally substituted carbon atoms and R is hydrogen, optionally substituted hydrocarbyl or acyl or --COOR.sup.7 and R.sup.7 is hydrocarbyl has anti-microbial properties. Particular examples are compounds in which X is --CH.sub.2 -- or --C(CH.sub.3).sub.2 -- and Y and Z are both --CH.sub.2 -- or X is is --CH.sub.2 -- and Y and Z are carbon atoms of a benzene ring. The zinc complexes have useful properties.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: Metallated compounds can be used to extract or precipitate proteins from solution. The compounds can be polymers, such as polyalkylene glycols, which can be mono- or bimetallated or smaller bis-metal chelates, such as ethylenebis(oxyethylenenitrilo)tetraacetic acid. The monometallated polymers are preferred in the extraction process whereas the bimetallated compounds are preferred in the precipitation process. In addition, new PEG compounds which are capable of chelating a variety of metals are described. Both mono- and bi-metallated forms are set forth. The new metallated compounds are very effective in extracting or precipitating proteins from solution.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: Antitumor acting platinum(II or IV) complexes of the general formula ##STR1## where B represents a phenyl-C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted in the phenyl nucleus by the radical R.sub.1 and R.sub.1 is hydrogen, halogen, trihalogen methyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or C.sub.2 -C.sub.6 -alkanoyloxy or where B together with the structural part H.sub.2 N-CR.sub.2 < forms a tetrahydroisoquinoline radical, if B contains benzyl and R.sub.2 hydrogen and the benzyl radical in the 2-position contains the CH.sub.2 -radical or where B together with the structural part --CR.sub.2 < represents a tetrahydronaphthyl radical in which one CH.sub.2 group is optionally replaced by oxygen, or where B together with the structural part --CR.sub.2 < represents a decahydronaphthyl radical or an indanyl radical; R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 -alkyl, phenyl or phenyl-C.sub.1 -C.sub.4 -alkyl, it also being possible for the phenyl ring of this group R.

Abstract: Metal complexes of azines of the formula ##STR1## in which X denotes hydrogen or halogen,R denotes hydrogen or an organic radical,R.sub.1 denotes hydrogen or an organic radical,R.sub.2 denotes an organic radical, in which R.sub.1 and R.sub.2 together with the C atom linking them can also form a carbocyclic or heterocyclic ring or a carbocyclic or heterocyclic ring system in which the rings and ring systems mentioned can also be substituted, and one of the radicals R.sub.1, R.sub.2 or R.sub.1 and R.sub.2 together contain a group capable of forming a metal salt, and processes for pigmenting using these metal complexes.

Abstract: A chiral catalyst is disclosed together with methods of using it for enantioselective syntheses. The chiral catalyst includes a nucleus with two metal atoms that has four bridging ligands oriented radially to the axis of the nucleus. Each of these ligands includes two complexing atoms each complexed to one of the metal atoms. At least one of the bridging ligands includes a chiral center which is bonded to one of the complexing atoms. Preferably, all four of the bridging ligands include a chiral center bonded to one of the complexing atoms. The catalyst of the invention has been found to be useful in catalyzing carbenoid transformation reactions such as cyclopropanation.

Abstract: Liquid crystalline polyesteretherimides are prepared by a transesterification reaction involving terephthalic acid and acylated derivatives of 4-hydroxybenzoic acid and of certain bisimidodiphenols, or from the free bisimidodiphenol and aryl esters of the acids. In addition to being liquid crystalline, the polyesterethermides are crystalline in the solid state and have relatively high glass transition temperatures.

Abstract: Platinum complexes of cis-diaminocyclohexanol or cis-diaminocyclohexane, with the exclusion of platinum complexes of 2-deoxystreptamine, having high anti-tumor activity, low toxicity, water-solubility and exhibiting no cross-resistance to cis-platin.

Abstract: 1,2-Bis(aminomethyl)-cyclobutane-platinum complexes having an anti-tumor activity.

Abstract: Bifunctional molecules having a DNA intercalator or DNA groove binder linked to ethylene diamine tetraacetic acid such as compounds having the formula: ##STR1## wherein R is methyl or ethyl. Also, the method of cleaving DNA by contact with one of the above-identified molecules in the presence of ferrous ion and oxygen.The process of preparing said molecules by the reaction of P-carboxy methidium halide, p-carboxy ethidium halide, or other DNA intercalator or DNA groove binder with 1-3-diaminopropane followed by condensation with ethylenediamine tetraacetic acid.Distamycin-EDTA.Fe(II)(DE.FE(II)) contains EDTA attached to the amino terminus of the groove binder tripeptide (tris-N-methylpyrrolecarboxamide). De.Fe(II) cleaves DNA contiguous to a five base pair A+T rich sequence. This is a novel and unique molecule and superior in sequence specificity to the naturally occurring antitumor compound used in man, bleomycin which cleaves DNA at a two base pair recognition site. EDTA-distamycin-Fe(II)(ED.

Abstract: This disclosure sets forth a novel process for producing cisplatin analogs which possess antitumor activity.

Abstract: Preparation of ethylene copolymers from ethylene and polar and/or non-polar comonomers in the presence of selected nickel-containing catalysts.

Abstract: Novel organic platinum complex of the formula: ##STR1## wherein R.sup.1 is hydrogen atom or a lower alkyl group; R.sup.2 is hydrogen atom, a substituted or unsubstituted lower alkyl group, a lower alkenyl group, a lower alkynyl agroup, a lower alkoxy group, a lower alkanoyl group, amino group, a substituted or unsubstituted nitrogen-containing hetero-monocyclic group, or an oxygen-containing hetero-monocyclic group, Alk is a lower alkylene group, X is carbonyl or sulfonyl group, n is 1 or 2, which has excellent anti-tumor activity against various tumors and is useful as an anti-tumor agent, and a process for the preparation thereof, and a pharmaceutical composition containing said compound.

Abstract: Essentially pure acid hydroxyl ligand aluminum complexes useful as antacids are prepared by first reacting an acid hydroxyl ligand with an aluminum alkoxide under anhydrous conditions to form an intermediate and further reacting the intermediate with water, these complexes are useful as antacids and as such in the treatment of hyperacidity.

Abstract: This invention relates to novel compositions of matter which are multifunctional amino zirconium aluminum metallo organic complexes which are comprised of a chemically united complex aluminum moiety, a tetravalent zirconium moiety, and a multifunctional amino acid wherein the acid is chemically bound to both the aluminum and zirconium centers.Such compositions are useful in promoting adhesion of adhesives, sealants, and coatings to metal, rubber, glass, plastic, coatings, and wood thereby enhancing strength properties and prolonging useful service life when such products are exposed to aggressive environments.Futher described is the specific process for the preparing of such compositions in organic media with desirable stability of the metal centers toward polymerization and related hydrolysis.

Abstract: Compounds of the formula ##STR1## wherein Het is a 5- or 6-membered aromatic heterocyclic ring containing 1 to 2 ring nitrogen atoms and the remaining ring atoms carbon atoms optionally substituted with 1 to 2 substituents independently selected from halo, nitro, trihalomethyl, lower alkyl of 1 to 3 carbon atoms, or lower alkoxy of 1 to 3 carbon atoms; R is alkyl of 1 to 7 carbon atoms; R.sup.1 is aryl of 6 to 10 carbon atoms, lower alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, all optionally substituted with 1 to 3 halogen atoms; and a is 0 or 1 are fungicidal and insecticidal, with the proviso that a ring nitrogen is not bonded to the hydroxamic acid ##STR2## moiety.

Abstract: Pigments of the formula ##STR1## in which Me=Zn, Cu, Co or preferably Ni,R=alkyl, cycloalkyl, aralkyl, aryl and hetaryl, where the mentioned radicals can be substituted, andAr=optionally substituted aryl,processes for their preparation, and their use.

Abstract: Novel bifunctional molecules having a DNA intercalator or DNA groove binder linked to ethylene diamine tetraacetic acid such as compounds having the formula: ##STR1## wherein R is methyl or ethyl. Also, the method of cleaving DNA by contact with one of the above-identified molecules in the presence of ferrous ion and oxygen.The process of preparing said molecules by the reaction of P-carboxy methidium halide, p-carboxy ethidium halide, or other DNA intercalator or DNA groove binder with 1-3-diaminopropane followed by condensation with ethylenediamine tetraacetic acid.Distamycin-EDTA.Fe(II)(DE.FE(II)) contains EDTA attached to the amino terminus of the groove binder tripeptide (tris-N-methylpyrrolecarboxamide). DE.Fe(II) cleaves DNA contiguous to a five base pair A+T rich sequence. This is a novel and unique molecule and superior in sequence specificity to the naturally occurring antitumor compound used in man, bleomycin which cleaves DNA at a two base pair recognition site. EDTA-distamycin-Fe(II)(ED.

Abstract: A method for alleviating cisplatin compound-induced nephrotoxicity in animals comprising administering to the animal an effective amount of a polar dithiocarbamate compound. The polar dithiocarbamate compounds have the formula: ##STR1## In the above formula, R.sup.1 and R.sup.2 are hydrocarbon groups and R.sup.1, R.sup.2, or both R.sup.1 and R.sup.2 contain a polar group substituted thereon. M is a pharmaceutically acceptable cation and n is an integer of from 1 to 3.Novel polar dithiocarbamate compounds are disclosed as well.

Abstract: 1-Unsubstituted .beta.-oxo-.alpha.-(phenylcarbamoyl)-.beta.-pyrrolylpropionitriles, e.g. those of the formula ##STR1## wherein R.sub.1 and R.sub.2 =H or alkyl, and R.sub.3 and R.sub.4 =H, alkyl, alkoxy, OH, halogen or CF.sub.3, are analgesic, and antiarthritic agents. Their synthesis, pharmaceutical compositions thereof, and methods of treatment utilizing such compounds are included.

Abstract: A chiral catalyst is disclosed together with methods of using it for enantioselective syntheses. The chiral catalyst includes a nucleus with two metal atoms that has four bridging ligands oriented radially to the axis of the nucleus. Each of these ligands includes a two complexing atoms each complexed to one of the metal atoms. At least one of the bridging ligands includes a chiral center which is bonded to one of the complexing atoms. Preferably, all four of the bridging ligands include a chiral center bonded to one of the complexing atoms. The catalyst of the invention has been found to be useful in catalyzing carbenoid transformation reactions such as cyclopropanation.